Brief: Fusen Pharmaceutical Says Eltrombopag Olamine Tablets Approved For Marketing By China NMPA
21/10/2024 16:35
Oct 21 (Reuters) - Fusen Pharmaceutical Co Ltd
1652.HK :
* ELTROMBOPAG OLAMINE TABLETS APPROVED FOR MARKETING BY
CHINA NMPA
Further company coverage: 1652.HK
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA